Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.65 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.62 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 11/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917716 | 0.83 | NUDT1 (0.61) | NUDT1TLR8TLR7PRKCQJAK2 | |
| SCHEMBL4201396 | 0.81 | NUDT1 (0.68) | NUDT1TLR8TLR7PRKCQJAK2 | |
| SCHEMBL856851 | 0.80 | IKBKB (0.66) | NUDT1PRKCQJAK2ROCK1 | |
| SCHEMBL23115440 | 0.78 | TLR8 (1.00) | TLR8TLR7TLR9 | |
| SCHEMBL30586760 | 0.78 | TLR8 (1.00) | TLR8TLR7TLR9 | |
| SCHEMBL9917924 | 0.78 | PRKCQ (0.72) | NUDT1TLR8TLR7PRKCQJAK2 | |
| SCHEMBL9917925 | 0.76 | NUDT1 (0.62) | NUDT1TLR8TLR7PRKCQJAK2 | |
| SCHEMBL9917767 | 0.76 | NUDT1 (0.58) | NUDT1TLR8TLR7PRKCQJAK2 | |
| SCHEMBL9917923 | 0.76 | PRKCQ (0.80) | NUDT1TLR8TLR7PRKCQJAK2 | |
| SCHEMBL2926257 | 0.75 | NUDT1 (0.59) | NUDT1TLR8TLR7PRKCQJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367697-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367697-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120149680-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149680-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-8173635-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173635-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090291937-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
| US-20090291937-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291937-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | NUDT1 1351/4885TLR8 4266/4885TLR7 4027/4885 |
| US-20120149680-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | NUDT1 1351/4885TLR8 4266/4885TLR7 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.